Olema Oncology, Inc. OLMA
7.02 USD -0.13 (-1.82%)
Regular-session close
7.02 0.00 0.00%
After hours · Nov 20, 4:01 PM ET
6.88 Day range 7.35
6.41 52-week range 35.83
- YTD
- -71.92%
- 1 year
- -68.11%
News
benzinga.com Olema Reports Selective KAT6A Degraders Potently Inhibit Proliferation In Diverse ER+/HER2- Breast Cancer Models, Active In ESR1-Mutant And Wild-Type, Well-Tolerated Orally bioavailable KAT6A degraders demonstrated potent antiproliferative activity in diverse in vivo models of ER+/HER2- breast cancerKAT6A degradation was active in both ESR1-mutant and wild-type…
globenewswire.com Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium SAN FRANCISCO, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization…
seekingalpha.com Olema Oncology, Inc. (OLMA) Olema Pharmaceuticals, Inc. Presents at UBS Global Biopharma Conference 2026 Transcript Olema Oncology, Inc. ( OLMA ) Olema Pharmaceuticals, Inc. UBS Global Biopharma Conference 2026 November 17, 2026 10:20 AM EST Company Participants Sean Bohen - President, CEO & Director Conference…
globenewswire.com Olema Oncology to Participate in Upcoming Investor Conferences SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization…benzinga.com Olema Pharmaceuticals Q3 EPS $(0.73) Misses $(0.63) Estimate Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.63) by 17.74 percent. This is a 48.98 percent decrease over…
